by michaelhalassa | Jul 16, 2025 | Cobenfy, Algorithmic psychiatry, Computational psychiatry, Distributed neural systems, Dopamine and psychosis, KarXT, Mental health treatment, Michael Halassa, muscarinic antipsychotic, Schizophrenia treatment, Xanomeline
I had the privilege of attending and in part organizing the inaugural Innovation in Psychosis Therapeutics Summit in Boston (June 9-11, 2025). This intimate gathering brought together scientists, clinicians and biotech leaders who share a common goal: to finally push...
by | May 14, 2025 | Cobenfy, KarXT
What Cobenfy Teaches Us About the Future of Psychiatric Drug Development The approval of Cobenfy (xanomeline-trospium) marks more than just the arrival of a new antipsychotic. It’s a signal—subtle but decisive—that the center of gravity in psychiatry may be shifting....
